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SUMMARY
The unique metabolic profile of cancer (aerobic glycolysis) might confer apoptosis resistance and be
therapeutically targeted. Compared to normal cells, several human cancers have high mitochondrial
membrane potential (DJm) and low expression of the K+ channel Kv1.5, both contributing to apopto-
sis resistance. Dichloroacetate (DCA) inhibits mitochondrial pyruvate dehydrogenase kinase (PDK),
shifts metabolism from glycolysis to glucose oxidation, decreases DJm, increases mitochondrial
H2O2, and activates Kv channels in all cancer, but not normal, cells; DCA upregulates Kv1.5 by an
NFAT1-dependent mechanism. DCA induces apoptosis, decreases proliferation, and inhibits tumor
growth, without apparent toxicity. Molecular inhibition of PDK2 by siRNA mimics DCA. The mitochon-
dria-NFAT-Kv axis and PDK are important therapeutic targets in cancer; the orally available DCA is
a promising selective anticancer agent.INTRODUCTION
Cancer progression and its resistance to treatment de-
pend, at least in part, on suppression of apoptosis. Al-
though mitochondria are recognized as regulators of apo-
ptosis, their importance as targets for cancer therapy has
not been adequately explored or clinically exploited. In1930, Warburg suggested that mitochondrial dysfunction
in cancer results in a characteristic metabolic phenotype,
that is, aerobic glycolysis (Warburg, 1930). Positron emis-
sion tomography (PET) imaging has now confirmed that
mostmalignant tumorshave increasedglucoseuptakeand
metabolism. This bioenergetic feature is a good marker
of cancer but has not been therapeutically pursued, as itSIGNIFICANCE
The small molecule DCA is a metabolic modulator that has been used in humans for decades in the treatment of
lactic acidosis and inherited mitochondrial diseases. Without affecting normal cells, DCA reverses the metabolic-
electrical remodeling that we describe in several cancer lines (hyperpolarized mitochondria, activated NFAT1,
downregulated Kv1.5), inducing apoptosis and decreasing tumor growth. DCA in the drinking water at clinically
relevant doses for up to 3 months prevents and reverses tumor growth in vivo, without apparent toxicity and with-
out affecting hemoglobin, transaminases, or creatinine levels. The ease of delivery, selectivity, and effectiveness
make DCA an attractive candidate for proapoptotic cancer therapy which can be rapidly translated into phase II–III
clinical trials.Cancer Cell 11, 37–51, January 2007 ª2007 Elsevier Inc. 37
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A Metabolic-Electrical Remodeling in Canceris thought to be a result and not a cause of cancer; that is,
the cells relymostly onglycolysis for energyproductionbe-
cause of permanent mitochondrial damage, preventing
oxidative phosphorylation. However, whether the mito-
chondria in cancer are indeed damaged and whether this
is reversible remain unknown.
The metabolic hypothesis of cancer has recently been
rekindled. Gatenby and Gillies recently proposed that be-
cause early carcinogenesis occurs in a hypoxic microen-
vironment, the transformed cells initially have to rely on
glycolysis for energy production (Gatenby and Gillies,
2004). However, this early metabolic adaptation appears
to also offer a proliferative advantage, suppressing apo-
ptosis. Furthermore, the ‘‘byproducts’’ of glycolysis (i.e.,
lactate and acidosis) contribute to the breakdown of the
extracellular matrix, facilitate cell mobility, and increase
the metastatic potential. Therefore, even though the tu-
mors eventually become vascularized and O2 levels in-
crease, the glycolytic phenotype persists, resulting in the
‘‘paradox’’ of glycolysis during aerobic conditions (the
Warburg effect). Metabolic and apoptotic pathways that
converge in the mitochondria are not independent from
each other, and it appears that glycolytic phenotype is in-
deed associated with a state of apoptosis resistance (Plas
and Thompson, 2002). Many glycolytic enzymes have
been recognized to also regulate apoptosis, and several
oncoproteins induce the expression of glycolytic enzymes
(Kim and Dang, 2005). For example, Akt, which stimulates
glycolysis and induces resistance to apoptosis (Elstrom
et al., 2004), activates hexokinase, an enzyme catalyzing
the first and irreversible step in glycolysis. Via its down-
stream mediator glycogen synthase kinase 3 (GSK3),
Akt induces the translocation of hexokinase to the mito-
chondrial membrane where it binds to the voltage-depen-
dent anion channel (VDAC), suppressing apoptosis (Kim
and Dang, 2005; Pastorino et al., 2005). Inhibition of
GSK3 in cancer cells causes unbinding of hexokinase
from VDAC, induces apoptosis, and increases sensitivity
to chemotherapy (Pastorino et al., 2005). This suggests
that perhaps the metabolic phenotype in cancer is due
to a potentially plastic mitochondrial remodeling that re-
sults in suppressed oxidative phosphorylation, enhanced
glycolysis, and suppressed apoptosis.
Whether the metabolism of glucose will end with glycol-
ysis in the cytoplasm (converting pyruvate to lactate) or
continue with glucose oxidation in the mitochondria is
controlled by a gate-keeping mitochondrial enzyme, pyru-
vate dehydrogenase (PDH) (Figure 1). PDH converts pyru-
vate to acetyl-CoA which, along with the acetyl-CoA from
the fatty acid b-oxidation, is fed to the Krebs cycle, pro-
ducing the electron donors NADH and FADH2. NADH
donates electrons to complex I of the electron transport
chain (ETC) (and FADH2 to complex III). The flux of elec-
trons down the ETC is associated with production of reac-
tive oxygen species (ROS) and with the efflux of H+, which
causes a negative mitochondrial membrane potential
(DJm). The F1F0-ATP synthase uses the stored energy
of the DJm to synthesize ATP; thus the DJm reflects
ETC activity and mitochondrial function. PDH is inhibited38 Cancer Cell 11, 37–51, January 2007 ª2007 Elsevier Inc.by phosphorylation by PDH kinase (PDK). The role of
PDH and PDK in cancer is unknown.
Mitochondrial remodeling has multiple downstream ef-
fects, beyond energy production, because mitochondria
regulate several critical functions including [Ca2+]i and
ROS-redox control. Through the release of ROS, mito-
chondria regulate the opening of plasma-membrane ion
channels and through the control of [Ca2+]i, regulate
Ca2+-sensitive transcription factors. Some of these down-
stream pathways are also important in apoptosis and
might contribute to the apoptosis resistance in cancer.
For example, inhibition or downregulation of K+ channels
results in increased [K+]i, by decreasing the tonic efflux
of K+ down its intracellular/extracellular gradient (145/5
mEq). Because [K+]i exerts a tonic inhibitory effect on
caspases, K+ channel inhibition or downregulation sup-
presses apoptosis in several cell types, including cancer
(Andersson et al., 2006; Remillard and Yuan, 2004;
Wang et al., 2002; Yu et al., 1997). The voltage-gated
family of K+ channels (Kv) is redox sensitive and therefore
can be regulated by mitochondria. For example, mito-
chondria-derived H2O2 (a relatively stable ROS) can acti-
vate Kv1.5 (Caouette et al., 2003). Furthermore, the mito-
chondria-derived proapoptotic mediator cytochrome c
activates, whereas the antiapoptotic bcl-2 inhibits, Kv
channels (Remillard and Yuan, 2004). This mitochondria-
ROS-Kv channel axis is now recognized as a basis of
an important O2-sensing mechanism in many tissues
(Michelakis et al., 2004).
In preliminary experiments, we compared several can-
cer with normal cell lines and found that cancer cells
hadmore hyperpolarizedmitochondria andwere relatively
deficient in Kv channels. If this metabolic-electrical re-
modeling is an adaptive response, then its reversal might
increase apoptosis and inhibit cancer growth. We used
dichloroacetate (DCA), a small, orally available small mol-
ecule and a well-characterized inhibitor of PDK (Bowker-
Kinley et al., 1998; Knoechel et al., 2006; Stacpoole,
1989). As seen in Figure 1, inhibition of PDK shifts pyruvate
metabolism from glycolysis and lactate production to
glucose oxidation in the mitochondria. The ability of DCA
to decrease lactate production has been used for more
than 30 years in the treatment of lactic acidosis that com-
plicates inherited mitochondrial diseases in humans
(Stacpoole et al., 1988, 2006).
We hypothesized that the downstream effects of the
DCA-induced shift in metabolism will have beneficial ef-
fects in cancer therapy (Figure 1). We show that, as pre-
dicted, DCA changes the metabolism of cancer cells
from the cytoplasm-based glycolysis to the mitochon-
dria-based glucose oxidation. This is associated with in-
creased production of ROS and decreased DJm in all
cancer, but not normal, cells, efflux of proapoptotic medi-
ators from the mitochondria, and induction of mitochon-
dria-dependent apoptosis. DCA also reverses the inhibi-
tion and downregulation of Kv1.5 in all cancer, but not
normal, cells. The resultant efflux of K+, and decrease in
intracellular K+, further increases the proapoptotic effects
of DCA. DCA effectively decreases tumor growth in vitro
Cancer Cell
A Metabolic-Electrical Remodeling in CancerFigure 1. A Reversible Metabolic-Electrical Remodeling in Cancer Contributes to Resistance to Apoptosis and Reveals Several
Potential Therapeutic Targets
In cancer, mitochondrial glucose oxidation is inhibited and energy production relies on the cytoplasmic glycolysis. This ‘‘inactivity’’ of the mito-
chondria likely induces a state of apoptosis resistance. Activation of PDH by DCA increases glucose oxidation by promoting the influx of acetyl-
CoA into the mitochondria and the Krebs cycle, thus increasing NADH delivery to complex I of the electron transport chain, increasing the production
of superoxide, which in the presence of MnSOD is dismutated to themore stable H2O2. Sustained increase in ROS generation can damage the redox-
sensitive complex I, inhibiting H+ efflux and decreasing DJm. Opening of the DJm-sensitive mitochondrial transition pore (MTP) allows the efflux of
cytochrome c and apoptosis inducing factor (AIF). Both cytochrome c and H2O2 open the redox-sensitive K
+ channel Kv1.5 in the plasma membrane
and hyperpolarize the cell (increased Em), inhibiting a voltage-dependent Ca2+ entry. The decreased [Ca2+]i suppresses a tonic activation of NFAT,
resulting in its removal from the nucleus, thus increasing Kv1.5 expression. The increased efflux of K+ from the cell decreases the tonic inhibition of
[K+]i on caspases, further enhancing apoptosis. DCA’s selectivity is based on its ability to target the unique metabolic profile that characterizes most
cancers, and its effectiveness is explained by its dual mechanism of apoptosis induction, both by depolarizing mitochondria (proximal pathway) and
activating/upregulating Kv1.5 (distal pathway).and in vivo. We show that a metabolic-electrical remodel-
ing regulates apoptosis resistance in cancer. Moreover,
this abnormality is easily reversible by a simple drug that
is already used in humans.
RESULTS
Cancer Mitochondria Are Hyperpolarized and Have
Suppressed Oxidative Metabolism, Both of which
Are Reversed by DCA
We studied DJm in three human cancer cell lines: A549
(non-small-cell lung cancer), M059K (glioblastoma), and
MCF-7 (breast cancer), and compared them with healthy,
noncancerous human cell lines: small airway epithelial
cells (SAEC), fibroblasts, and pulmonary artery smooth
muscle cells (PASMC). All cancer cell lines had signifi-cantly more hyperpolarized DJm compared to normal
cells (increased fluorescence of the DJm-sensitive posi-
tive dye tetramethyl rhodamine methyl ester; TMRM).
Incubation of all three types of cancer cells with DCA (48
hr) reversed the hyperpolarization and returned the DJm
to the level of the normal cells (n  80 cells, 10 plates/cell
line/group). In contrast, DCA did not alter the DJm of the
SAEC (Figure 2A), fibroblasts, andPASMC (not shown). The
DCA effects on mitochondrial DJm occurred as quickly
as 5 min and were dose dependent (Figure 2B). Because
the intracellular distribution of TMRM can theoretically
be affected by differences in the plasma-membrane po-
tential (Em), we used a protonophore (carbonylcyanide-p-
trifluoromethoxyphenylhydrazone; FCCP) and showed
that in all cancer cell lines it decreased DJm in a dose-
dependent manner, eventually depolarizing untreated andCancer Cell 11, 37–51, January 2007 ª2007 Elsevier Inc. 39
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A Metabolic-Electrical Remodeling in Cancerigure 2. DCA Reverses the Glycolytic Phenotype and Depolarizes Mitochondria in Cancer, but Not Healthy, Cells
) Forty-eight hours of DCA (0.5 mM) significantly depolarized A549, MO59K, and MCF-7 cancer cells, but had no effect on healthy SAEC.
) DCA depolarizes mitochondria acutely (5–10 min) and in a dose-dependent manner.
) DCA increases glucose oxidation and suppresses glycolysis and fatty acid oxidation in A549 cells.
and E) Forty-eight hours of DCA (0.5 mM) decreased extracellular lactate levels and increased pH in A549 cells, measured by the SNARF-1
tiometric dye.
< 0.05 versus control.DCA-treated cells at the same low DJm (see Figure S1 in
the Supplemental Data available with this article online).
This suggests that the TMRM signal was not confounded
by DCA effects on the Em, but was rather due to true
changes in the DJm.
To determine the effect of DCA onmetabolism, wemea-
sured glycolysis (Gl), glucose oxidation (GO), and fatty
acid oxidation (FAO) in A549 cells (10 plates/experiment,
n = 3). DCA significantly increased GO rates (+23%),
with a concomitant decrease in both Gl and FAO (Fig-
ure 2C). As expected from the DCA-induced shift of pyru-
vate metabolism away from lactate and toward acetyl-
CoA and the Krebs cycle, the lactic-acid levels in the
culture medium of the DCA-treated cells decreased
(Figure 2D, n = 10 plates/group) and the intracellular pH
increased (Figure 2E, n = 5 plates, 60 cells/group).
DCA Causes Efflux of Proapoptotic Factors from
Mitochondria and Increases ROS Production
Whereas the untreated cancer cells (A549) showed cyto-
chrome c and apoptosis-inducing factor (AIF) restricted0 Cancer Cell 11, 37–51, January 2007 ª2007 Elsevier Inc.to the mitochondria (colocalized with mitotracker red), in
the DCA-treated cells cytochrome c was diffusely present
in the cytoplasm and AIF was translocated to the nucleus
(Figure 3A), both indicating induction of apoptosis.
DCA increased H2O2 production in a dose-dependent
manner; this increase was inhibited by rotenone, suggest-
ing that it was based on complex I of the ETC (Figure 3B,
n = 5 plates/group). We also measured NADH levels in
isolated mitochondria and showed that DCA increased
the intramitochondrial NADH (Figure 3C, 5 plates/experi-
ment, n = 5). The DCA-induced decrease in DJm was
limited by the VDAC (an important component of the
mitochondrial transition pore; MTP) inhibitor 40-diisothio-
cyano-2,20-disulfonic acid stilbene (DIDS; 0.5 mM) (Gran-
ville and Gottlieb, 2003) (Figure 3D, n = 5, 60 cells/
group).
To determine whether cancer cells are less dependent
on the ETC and oxidative phosphorylation, we studied
the effects of low-dose cyanide (a complex-IV inhibitor
and a well-known poison for normal cells). Cyanide’s
effects on mitochondria (as measured by DJm) were
Cancer Cell
A Metabolic-Electrical Remodeling in CancerFigure 3. DCA Opens the MTP, Increases Intramitochondrial NADH and H2O2 Production, and Induces Mitochondrial Apoptosis in
A549 Cells
(A) Cytochrome c in green is colocalized with the mitotracker red staining in untreated cancer cells, whereas after 48 hr of DCA (0.5 mM) treatment,
cytochrome c leaks out of the mitochondria into the cytosol. In DCA-treated cells, apoptosis-inducing factor (AIF, red) is mainly localized in the
nucleus (i.e., activated), in contrast to the untreated A549 cells.
(B) DCA increases H2O2 production (*p < 0.05) in a dose-dependent manner (#p < 0.05), and this is almost completely inhibited by rotenone (5 mM)
(**p < 0.05), an inhibitor of mitochondrial electron transport chain complex I.
(C) DCA increases the intramitochondrial NADH inmitochondria isolated fromuntreated control andDCA-treated A549 cells (48 hr, 0.5mM) (*p < 0.05).
(D) The DCA-induced mitochondrial depolarization is inhibited by DIDS, an inhibitor of the mitochondrial VDAC, which is a critical component of MTP
(*p < 0.05).
(E) Cyanide (5mM)doesnot affectmitochondrial function (DJm) in cancer cells significantly, in contrast to theDCA-treated cells, supporting the relative
independence of cancer cells from the mitochondrial ETC (*p < 0.05).much less pronounced in cancer compared to the DCA-
treated cells (Figure 3E, n = 5, 60 cells/group).
DCA Activates Kv Channels in Cancer Cells
by an H2O2-Dependent Mechanism
Using whole-cell patch clamping, we showed that in all
untreated cancer cell lines the outward K+ current (Ik)
was small and essentially voltage independent. DCA in-
creased the Ik significantly in all cancer cell lines, but did
not alter the Ik in the noncancerous SAEC (Figure 4A),
PASMC, or fibroblasts (not shown) (Figure 4A, n = 7–8/
group). The increase in Ik occurred as early as 5 min andpersisted after 48 hr of DCA exposure. Most of the
increased Ik was voltage dependent and blocked by
4-aminopyridine, a specific Kv channel inhibitor. The
increased Ik caused hyperpolarization of the plasma-
membrane Em. DCA also decreased cell capacitance,
an electrophysiologic surrogate of cell size/volume, con-
sistent with the cell shrinkage that characterizes early
apoptosis (Figure 4A).
The DCA-induced increase in Ik was blocked by intra-
cellular catalase, delivered through the patch pipette
(i.e., due to H2O2), and by rotenone (i.e., due to complex
I-produced H2O2), but not by thenoyltrifluoroacetoneCancer Cell 11, 37–51, January 2007 ª2007 Elsevier Inc. 41
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A Metabolic-Electrical Remodeling in CancerFigure 4. DCA Activates a Kv Current and Induces the Expression of Kv1.5 in Cancer, but Not Healthy, Cells
(A) Forty-eight hours of DCA (0.5 mM) increases K+ current density (current amplitude/cell capacitance, pA/pF) in all cancer cell lines (A549, MO59K,
and MCF-7) but does not affect noncancerous SAEC. On the left, original traces representing the K+ current in both untreated and DCA-treated cells
are shown. The increase in K+ current density is mainly due to an increase in Kv current, as most of the increased current is 4-aminopyridine sensitive.
Current subtraction was performed and the DCA-induced Kv current is shown in the insets. DCA treatment also causes a significant decrease in
membrane capacitance and an increase in the plasma-membrane resting potential (*p < 0.05 versus control).
(B) Themechanism bywhich DCA increases K+ current was assessed by exposing cancer (A549) cells to DCA (0.5mM) acutely (5–10min). The effects
of DCA on K+ current were blocked by 4-aminopyridine (5 mM), catalase (10,000 units, intracellularly via pipette), and rotenone (5 mM), whereas
a specific blocker of complex II (TTFA, 1 mM) did not alter the DCA effects (*p < 0.05 versus control).
(C) DCA decreases [K+]i and this is inhibited when the K
+ gradient is diminished by adding extracellular KCl.
(D) DCA-treated cells (48 hr) have increased Kv1.5 mRNA and protein, compared to the untreated cells (*p < 0.05 versus untreated cells).(TTFA; an inhibitor of complex II of the ETC) (Figure 4B, n =
5). It was also not blocked by the human ether-a-go-go-
related gene (HERG) inhibitor E4031 (50 nM) (Wang
et al., 2002) (not shown). The activation of Kv channels
by DCA resulted in a decrease in intracellular K+, due
to efflux of K+ down its concentration gradient. When
this gradient was diminished by the addition of KCl, the
intracellular K+-lowering effects of DCA were inhibited
(Figure 4C, n = 20).
DCA Decreases [Ca2+]i and Increases Kv1.5
Expression via Inhibition of NFAT1
We have recently shown that DCA increases the expres-
sion of Kv1.5 in PASMC (McMurtry et al., 2004). Only
one study has linked Kv1.5 with cancer: Kv1.5 expression42 Cancer Cell 11, 37–51, January 2007 ª2007 Elsevier Inc.(but not other Kv channels) correlates with tumor grade
in human gliomas, that is, the higher the grade, the lower
the Kv1.5 (Preussat et al., 2003). We used quantitative
real-time polymerase chain reaction (n = 5) and immuno-
blots and showed that Kv1.5 is significantly increased in
DCA-treated A549 cancer cells (Figure 4D), in contrast
to Kir2.1, a K+ channel from a different family (not shown).
To study whether Kv1.5 expression correlates with
human tumor grade, we used archived tumors from a
cohort of 30 consecutive patients with non-small-cell lung
cancer. We measured both Kv1.5 and survivin expression
in each tumor sample and correlated their levels with his-
tologic tumor grade by blinded readers. Survivin, a marker
of resistance to apoptosis and tumor aggressiveness, has
recently been shown to regulate mitochondria-dependent
Cancer Cell
A Metabolic-Electrical Remodeling in CancerFigure 5. DCA Upregulates Kv1.5 by Decreasing [Ca2+]i and Inhibiting the Ca
2+-Dependent Transcription Factor NFAT1
(A) Free cytosolic calcium ([Ca2+]i) concentration wasmeasured using FLUO-3. Untreated A549 cells have higher [Ca
2+]i than both DCA- and t-butyryl-
H2O2-treated cells. The decrease in [Ca
2+]i by DCA and H2O2 is inhibited by 4-aminopyridine (5 mM), suggesting that it involves the opening of Kv
channels. It is also blocked by rotenone (5 mM), suggesting that it involves ROS produced in complex I. Lanthanum (10 mM) prevents the effects
of 4-aminopyridine (*p < 0.01, **p < 0.05, compared to untreated controls).
(B) Confocal imaging and triple-staining of A549 cells showed that NFAT1 (green) is activated, as it is mainly localized in the nuclei (stained blue by
DAPI) of most of the untreated cells. These cells have a very low level of Kv1.5 expression (red). Both DCA and H2O2 block the activation of NFAT1, as
it is mainly localized in the cytoplasm; the cells with the cytoplasmic NFAT1 have proportionately increased Kv1.5 expression. The NFAT inhibitor
VIVIT (4 mM) displaces NFAT1 from the nucleus and causes a significant upregulation of Kv1.5.
(C) Representative clinical specimens of non-small-cell lung cancer, showing that NFAT1 activation is associated with decreased Kv1.5 expression
and higher histologic grade. Within each sample, the lowest Kv1.5 expression is seen in cells with activated NFAT1 (arrows).
(D) By upregulating Kv1.5, VIVIT decreases [Ca2+]i, suggesting that the reason for increased [Ca
2+]i levels in the cancer cells involves a downregulation
of Kv1.5.
*p < 0.05 versus control.apoptosis in both cancer (Dohi et al., 2004) and vascular
tissues (McMurtry et al., 2005). Survivin correlated posi-
tively with tumor grade while Kv1.5 correlated negatively
(the higher the Kv1.5, the lower the grade), and no differ-
ences in the expression of Kir2.1 were seen (Figure S2).
Because NFAT (nuclear factor of activated T lympho-
cytes) inhibits both apoptosis (Pu et al., 2003) and the
expression of Kv1.5 in myocardial cells (Rossow et al.,
2004), we speculated that this could also occur in cancer.
Increases in [Ca2+]i activate calcineurin, which dephos-
phorylates NFAT, allowing its translocation to the nucleus
where it regulates gene transcription (Macian, 2005). We
hypothesized that the DCA-induced activation of Kv1.5
leads to plasmalemmal hyperpolarization, inhibiting
voltage-gated Ca2+ channels (which are active even in
nonexcitable cells; Dietl et al., 1995), decreasing [Ca2+]i,thereby inhibiting NFAT and enhancing Kv1.5 expression
(Figure 1).
As predicted, DCA-treated A549 cells have lower [Ca2+]i
compared to untreated cells (Figure 5A). The decrease in
[Ca2+]i occurs within 5 min and is sustained after 48 hr of
DCA exposure. At both time points, DCA’s effects on
[Ca2+]i are inhibited by 4-aminopyridine and rotenone
and are mimicked by t-butyryl-H2O2, suggesting that
they involve opening of Kv channels by complex I-derived
H2O2 (n 20 plates/group). The 4-aminopyridine-induced
increase in [Ca2+]i in the DCA-treated cells is inhibited
by lanthanum (n = 6), a blocker of Ca2+ entry into the cell
(Figure 5A), confirming an operative voltage-dependent
pathway of Ca2+ entry.
NFAT1 activation (defined by its translocation to the
nucleus) is evident in the majority of untreated A549Cancer Cell 11, 37–51, January 2007 ª2007 Elsevier Inc. 43
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A Metabolic-Electrical Remodeling in CancerFigure 6. DCA Induces Apoptosis and Decreases Proliferation in Cancer Cells by a Dual Mechanism Involving Mitochondria and
Upregulation of Kv1.5
(A) DCA increases apoptosis in A549 cells as shown by the expression of annexin and the increased % of TUNEL-positive cells (mean data in [D]),
compared to the untreated controls. The absence of propidium iodide (PPI) staining in the annexin-positive cells suggests that the cells were
apoptotic and not necrotic. DCA activates both caspase 3 and 9, as immunoblots reveal an active band for both caspases.
(B) DCA treatment decreases cell proliferation, measured by PCNA (mean data in [D]) and BrdU. DCA also decreases the expression of survivin.
(C and D) Kv1.5 gene transfer using Ad-GFP-Kv1.5 adenovirus increases the K+ current and induces apoptosis (for these experiments, TUNEL is red in
GFP-positive cells), compared to the cells infected with Ad-GFP (C). However, this exogenous gene transfer of human Kv1.5 causes less apoptosis
and smaller inhibition of proliferation compared to the DCA-treated cells (D), despite a larger increase in the outward K+ current (compare with
Figure 4). 4-aminopyridine decreases DCA-induced apoptosis by 32% (also see Figure S4).
*p < 0.05 versus controls.cells, and in these cells Kv1.5 expression is low (Figure 5B).
In contrast, in DCA-treated cells, NFAT1 is mostly cyto-
plasmic and Kv1.5 expression is proportionately in-
creased. As with Ik (Figure 4B) and [Ca2+]i (Figure 5A), the
effects of DCA on NFAT1 were mimicked by t-butyryl-
H2O2 (Figure 5B). We then treated A549 cells with VIVIT,
a competing peptide that selectively blocks NFAT-
regulated mechanisms due to its ability to block calci-
neurin docking on NFAT, preventing its activation without
inhibiting calcineurin’s catalytic site (Aramburu et al.,
1999). The VIVIT-treated cells show displacement of
NFAT1 from the nucleus and increased Kv1.5 expres-
sion (Figure 5B). The same was true for cells treated
with cyclosporine, a nonspecific inhibitor of calcineurin
(Figure S3A).
In human non-small-cell lung tumors costained with
anti-Kv1.5, anti-NFAT1, and 40,6-diamidino-2-phenylin-
dole (DAPI), low-grade histology was associated with
high Kv1.5 expression and low NFAT1 expression, most44 Cancer Cell 11, 37–51, January 2007 ª2007 Elsevier Inc.of which was cytoplasmic; the reverse pattern was seen
in high-grade tumors (Figure 5C).
The effects of NFAT1 might be potentiated by a posi-
tive feedback loop: low Kv1.5 / depolarized plasma
membrane / Ca2+ influx / high [Ca2+]i / activated
NFAT / low Kv1.5. NFAT inhibition effectively breaks
this loop because VIVIT decreases [Ca2+]i (n = 5 plates/
group, Figure 5D).
DCA Induces Mitochondria-Dependent Apoptosis
and Decreases Proliferation In Vitro
DCA increases annexin expression, causes a 6-fold
increase in the percentage of TUNEL-positive nuclei,
and activates both caspase 3 and 9 in A549 cells (Fig-
ures 6A and 6D). Eliminating highly proliferative cells
by the induction of apoptosis, and by decreasing
[Ca2+]i levels, DCA decreases indices of proliferation (Fig-
ures 6B and 6D) including BrdU incorporation and
expression of proliferating cell nuclear antigen (PCNA).
Cancer Cell
A Metabolic-Electrical Remodeling in CancerIn addition, DCA decreases the expression of survivin
(Figure 6B).
DCA-induced apoptosis proceeds by two pathways,
one in the mitochondria, where depolarization activates
mitochondria-dependent apoptosis, and the other at the
plasmalemmal level, where activation/upregulation of
Kv1.5 channels decreases [K+]i, activating caspases. To
determine the relative importance of the twomechanisms,
we compared the apoptosis induced by DCA to the apo-
ptosis induced by a primary increase in Kv1.5 expression,
using adenoviral gene transfer (Figures 6C and 6D). Com-
pared to the adenovirus carrying green fluorescent protein
(GFP) only, the adenovirus carrying GFP and cloned hu-
man Kv1.5 (Pozeg et al., 2003) significantly increased the
percentage of TUNEL-positive cells. However, although
the increase in Ik achieved with the gene transfer was
higher than the increase achieved by DCA (Figure 6C;
compare with Figure 4A), the increase in apoptosis
achieved by the gene transfer was significantly less than
that achieved by DCA (Figure 6D). We then measured the
DCA-induced apoptosis in the presence of 4-aminopyri-
dine (5 mM), a blocker of the whole Kv family. In addition
to the A549 cells we also studied glioblastoma, an excit-
able cell type in which Kv channels might be more impor-
tant in apoptosis regulation compared to the epithelial
A549 cells. In the presence of 4-aminopyridine, DCA
induced 68%of the apoptosis (%TUNEL-positive cells) in-
duced by DCA alone (Figure 6D). Similarly, in glioblastoma
cells, DCA + 4-aminopyridine induced 62% of the apopto-
sis induced by DCA alone (Figure S4). Moreover, 4-amino-
pyridine did not limit DCA’s ability to cause efflux of
cytochrome c from mitochondria, initiating mitochondria-
based apoptosis (Figure S4). These data underlie the
preponderant importance of themitochondrial component
of DCA’s proapoptotic actions.
That NFAT1 is a distal mediator in DCA’s anticancer
effects was supported by the fact that VIVIT increased
apoptosis and decreased proliferation in a manner similar
to DCA (Figure S3B). For imaging studies, we studied four
random fields per slide for30 slides/group, and for patch
clamping, 6–8 cells/group.
Molecular Inhibition of PDK2 Mimics DCA
To confirm that inhibition of PDK is the major mechanism
for the effects of DCA, we determined whether molecular
inhibition of PDK2 by siRNAmimics DCA.We chose PDK2
because it is the only ubiquitously expressed isoenzyme;
PDK1 and 3 are restricted in the heart and testis, respec-
tively, and PDK4 is mostly expressed in skeletal muscle
and heart. PDK2 is the most active of all and also has the
lowest Ki for DCA (0.2 mM) (Bowker-Kinley et al., 1998).
siRNA for PDK2 inhibited the expression of PDK2 in a
dose-dependent manner, inhibiting mRNA up to 80% and
protein expression (measured by both immunoblots and
immunohistochemistry) by 70% (Figure S5). We tested
three commercially available PDK2 siRNAs, which all in-
hibited the gene in a similar manner. Scrambled siRNA for
PDK2 as well as siRNA for PDK1 did not decrease PDK2
expression (Figure S5).Whereas the scrambled siRNAhadno effect on A549 cells, PDK2 siRNA decreased DJmand
increasedmitochondrial ROS in amanner identical to DCA
(Figures 7A and 7B, n  20 plates/group). DCA added
to siRNA-treated cells had no additional effects (data not
shown). Inhibition of PDK2 by siRNA also increased apo-
ptosis and decreased proliferation in cancer cells (Fig-
ure 7C, n  30 plates/group). To further prove that DCA
activates PDH by inhibiting PDK, we immunoprecipitated
PDH and showed that DCA increased the nonphosphory-
lated fraction (i.e., active) of the catalytic subunit (E1a)
(Figure 7D).
DCA in the Drinking Water Induces Apoptosis
and Decreases Tumor Growth In Vivo
We studied nude athymic rats implanted subcutaneously
with 33 106 A549 cells. The rats had free access to water
with or without DCA (75 mg/l). In the first set of experi-
ments (protocol a), 21 animals were divided into three
groups: untreated controls (n = 5), DCA-prevention rats
(n = 8), which received DCA just after cell injection for
5 weeks, and DCA-reversal rats (n = 8), which received
DCA 2 weeks post-cell injection for 3 more weeks. The
untreated rats rapidly developed tumors with a constant
exponential tumor growth (Figure 8A). Both DCA-treated
groups had a significant decrease in tumor size, measured
by tumor weight at sacrifice and maximal diameter using
calipers; in some rats, in vivomagnetic resonance imaging
allowed us to visualize the tumors in vivo and calculate
their volume. The decrease in tumor growth by DCA was
associated with an increase in apoptosis (TUNEL) and
a decrease in proliferation (PCNA) (Figure 8B). There
was an inverse correlation between apoptosis and tumor
size in the treated rats (Figure 8B). Kv1.5 was upregulated
and survivin was downregulated in the DCA-treated
rats (Figure 8C), confirming our in vitro data (Figures 4
and 6).
In a second set of experiments (protocol b), we studied
whether the effects of DCA were sustained for longer
periods of time and whether DCA would have a similar
effect inmore advanced tumors.We followed three groups
of rats (n = 6/group) for 12 weeks: an untreated control
group, a prevention group (rats given DCA at the time of
tumor cell injection), and a reversal group where rats
were given DCA at week 10 for 2 weeks. As in protocol
a, at all times rats in the prevention group had significantly
smaller tumors compared to the untreated controls; DCA
at week 10 inhibited tumor growth immediately, with a
significant decrease even after 1 week of treatment. DCA
therapy did not have any toxic effects, as measured
by several blood tests (Figure 8D; also see McMurtry
et al., 2004).
DISCUSSION
Here we show that a metabolic-electrical remodeling
(hyperpolarized mitochondria, downregulated Kv chan-
nels) regulates the apoptosis resistance that characterizes
multiple human cancers. DCA, a small molecule that
targets mitochondria, reverses this remodeling, inducingCancer Cell 11, 37–51, January 2007 ª2007 Elsevier Inc. 45
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(A) Effective inhibition of PDK2 expression by siRNA (see Figure S1) depolarizes A549 mitochondria in a manner similar to DCA, whereas scrambled
siRNA has no effect.
(B) siRNA inhibition of PDK2 also mimics DCA in increasing mitochondria-derived ROS, as measured with the fluorescent dye mitosox.
(C) siRNA inhibition of PDK2 increases apoptosis (% TUNEL-positive cells), similar to DCA.
(D) Human PDH was immunoprecipitated from A549 cells and treated with a cocktail of monoclonal antibodies against several PDH subunits. In the
untreated cancer cells, the E1a subunit (i.e., the catalytic subunit) is all in the phosphorylated form, indicatingmaximal inhibition of PDH by PDK. In the
DCA-treated cells, the nonphosphorylated fraction of the E1a subunit is significantly increased, indicating an increase in the activity of PDH.
*p < 0.05 versus controls.apoptosis and decreasing cancer growth in vitro and
in vivo. These beneficial effects occur without affecting
noncancerous cells or eliciting systemic toxicity. DCA
treatment significantly increases glucose oxidation (which
only occurs in functional mitochondria), indicating that
the well-recognized, metabolic cancer signature (aerobic
glycolysis) is reversible, rather than a consequence of
permanent mitochondrial damage. DCA exerts its benefi-
cial effects by twopathways, both ofwhich induce apopto-
sis: first, by mitochondrial depolarization and efflux of
proapoptotic mediators, and second, by an increase in
Kv channel expression/function. DCA increases Kv chan-
nel expression by inhibiting NFAT1, a calcium-sensitive
transcription factor that regulates cell-differentiation pro-
grams in many cell types but which has previously been46 Cancer Cell 11, 37–51, January 2007 ª2007 Elsevier Inc.unexplored in cancer. The mitochondria-NFAT-Kv path-
way in cancer offers several new candidate targets for
proapoptotic therapy that would be predicted to have
high therapeutic selectivity.
Glycolysis and Cancer: Not Just an Epiphenomenon
It is nowwell accepted that most cancers have a glycolytic
phenotype. Warburg suggested, but did not prove, that
this was due to ‘‘abnormalmitochondria’’ (Warburg, 1930);
that is, cancer cells are forced to use inefficient, nonmito-
chondrial means of generating ATP. Our data suggest that
this apparent mitochondrial ‘‘dysfunction’’ is in fact re-
versible. Oxidative metabolism in cancer could be actively
suppressed; the resultant shift to glycolysis may lead to
apoptosis resistance (Plas and Thompson, 2002), offering
Cancer Cell
A Metabolic-Electrical Remodeling in CancerFigure 8. Decreased Tumor Size in DCA-Treated Nude Rats Is Due to an Increase in Apoptosis and Decrease in Cell Proliferation
(A) Injection of A549 cells into the flank of nude rats results in the development of measurable tumors within 1 week. DCA-treated rats in both the
prevention and reversal groups of protocols a and b (see Results) have smaller tumors. The size of the tumors was assessed by weight, calipers,
or magnetic resonance imaging in vivo and at the time of euthanasia, as shown.
(B) DCA-treated rats had smaller tumors due to a significant increase in apoptosis (TUNEL) and a decrease in proliferation (PCNA), as shown by triple-
staining. A significant correlation was observed between%TUNEL and both tumor diameter andweight (the higher the%of TUNEL-positive cells, the
smaller the tumor).
(C) In agreement with our in vitro data, DCA increases Kv1.5 and decreases survivin expression, as shown by both immunohistochemistry and
immunoblotting.
(D) DCA-treated rats did not have any sign of liver (AST), kidney (creatinine), or blood (hemoglobin) toxicity.
*p < 0.05 versus untreated controls.a survival advantage in the transformed cells (Gatenby and
Gillies, 2004). This suggests that a novel way to reverse
apoptosis resistance might be to undo this metabolic/mi-
tochondrial remodeling. We show that the glycolytic phe-
notype in cancer is easily altered by promoting oxidative
phosphorylation (Figure 2C). This is associated with mito-
chondrial depolarization, which facilitates apoptosis and
inhibits tumor growth. All the human cancer cell lines stud-
ied hadmore negativeDJmcompared to several noncan-
cerous cell lines (Figure 2A), suggesting that this might be
a hallmark of malignancy. Although apoptosis is not
always associated with mitochondrial depolarization, our
data are in agreement with the observation that cationic
lipophilic drugs preferentially accumulate to tumor mito-
chondria (Don and Hogg, 2004). In addition, the positively
charged rhodamine-based dyes (like TMRM) have been
tried as ‘‘carriers’’ for selective delivery of drugs in cancer.More than 200 carcinomas were screened and were
shown to accumulate rhodamine much more than non-
carcinoma cells; these findings were first reviewed in
1988 (Chen, 1988), and although the mechanism was not
clear then, it likely reflects the more negative DJmof can-
cer compared to noncancerous cells. Our work directly
shows that this relative increase inDJm is associatedwith
increased resistance to apoptosis, and its ‘‘normalization’’
increases apoptosis and decreases cancer growth. Fur-
thermore, it has just been shown that DJm of colon can-
cer cells predicts the aggressiveness of the tumor cells,
that is, the more hyperpolarized the DJm, the more
aggressive and metastatic the tumor (Heerdt et al.,
2005), in agreement with our proposal. Studying DJm in
fresh tumor specimens might be a convenient means to
predict resistance to proapoptotic chemotherapies, with
important implications in clinical decision making.Cancer Cell 11, 37–51, January 2007 ª2007 Elsevier Inc. 47
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Mitochondria, and Initiate Apoptosis?
The shift in the metabolism of pyruvate away from lactate
and toward acetyl-CoA and the Krebs cycle (Figures 2C
and 2D), caused by DCA or molecular inhibition of PDK2
(Figure 7), increases the intramitochondrial production of
the electron-donor NADH (Figure 3C), a substrate of the
ETCcomplex I, leading to increased complex I-basedROS
production (Figures 3Band7B) (Kushnareva et al., 2002). A
sustained increase in the ROS production can cause
oxidative damage in the ETC, particularly complex I. This
megacomplex is the most sensitive of all ETC complexes
to ROS damage because it is by far the largest (46 sub-
units), and has at least nine ROS-sensitive iron-sulfur cen-
ters and seven mitochondrial DNA-encoded subunits
(Brandt, 2006), which are very susceptible to oxidative
damage. The ROS-induced complex-I dysfunction can
limit the efflux of H+, decreasing DJm. Upon sustained
and significant decrease in DJm, the voltage-sensitive
MTP opens (Zamzami and Kroemer, 2001), allowing the
efflux of many proapoptotic factors and the initiation of
apoptosis (Figures 3A, 6, and 8B). This further increases
the production of mitochondrial ROS, likely reinforcing
a positive feedback loop enhancing apoptosis (Zamzami
and Kroemer, 2001).
This ‘‘complex I-centered’’ proposed mechanism has a
precedent in congenital mitochondrial syndromes and
neurodegenerative diseases. Patients with congenital
complex-I deficiency have decreasedDJmand increased
ROS production (Pitkanen and Robinson, 1996). Inhibition
of complex I in cell lines is associatedwithdecreasedDJm
and increased ROS production in a dose-dependent
manner, that is, thehigher thepercent complex-I inhibition,
the higher the ROS and the lower theDJm (Barrientos and
Moraes, 1999). A similar mechanism where dose-depen-
dent inhibition of complex I leads todose-dependent efflux
of cytochrome c and apoptosis (Clayton et al., 2005) is
proposed in the pathogenesis of neurodegenerative dis-
eases such as Parkinson’s, where complex-I dysfunction
and ROS-mediated oxidative damage are well described
(Bao et al., 2005; Schon and Manfredi, 2003).
Inhibition of VDAC limited the DCA-induced decrease in
DJm (Figure 3D). VDAC (along with the adenine nucleo-
tide translocase) is involved in the translocation of ADP
(a substrate for the F1F0-ATPase) from the cytoplasm
into the mitochondria. Inhibition of the VDAC would thus
inhibit the function of the F1F0-ATPase, which would
lead to accumulation of H+ in the intermembrane mito-
chondrial space, promoting hyperpolarization of the
DJm, thus limiting the depolarizing effects of DCA. This
is supported by findings from Thompson’s group (Vander
Heiden et al., 1999), although the role of VDAC in the reg-
ulation of DJmand initiation of apoptosis remains contro-
versial (Shimizu et al., 1999) (reviewed in Granville and
Gottlieb, 2003), and some of these mechanisms might
only be relevant to specific experimental conditions,
such as growth-factor withdrawal (Vander Heiden et al.,
1999). An additional intriguing possibility is that, because
DCA is itself an anion (see structure in Figure 1), it likely48 Cancer Cell 11, 37–51, January 2007 ª2007 Elsevier Inc.enters the mitochondria via the VDAC, explaining, at least
in part, why its inhibition limits the effects of DCA onDJm.
Unexpectedly, but consistent with its therapeutic bene-
fit, DCA decreased the expression of survivin, an inhibitor
of apoptosis, both in vitro and in vivo (Figures 6 and 8).
Survivin has recently emerged as a major antiapoptotic
oncoprotein. The mechanism by which survivin is down-
regulated is unclear. Recent observations describing the
direct involvement of a mitochondrial survivin pool in the
suppression of apoptosis suggest that survivin might
participate in the mitochondrial remodeling of cancer
(Dohi et al., 2004; McMurtry et al., 2005).
A Mitochondria-NFAT-Kv Channel Axis in Cancer Is
NormalizedbyDCA,Contributing to theProapoptotic
and Antiproliferative Effects of DCA
The apoptosis resistance in cancer likely involves multiple
mechanisms. The current findings highlight the con-
tribution of Kv channel inhibition/downregulation, due to
impaired mitochondrial signaling, to this resistance. Clos-
ing of K+ channels or decreasing their expression results
in an increase in [K+]i which increases the tonic inhibition
that cytosolic K+ exerts on caspases. Kv1.5 gene transfer
directly activated apoptosis in A549 cells (Figures 6C and
6D). Functional inhibition of all Kv channels by 4-amino-
pyridine limited the DCA-induced apoptosis by 32% in
A549 cells and by 38% in glioblastoma cells (Figure 6D;
Figure S4), suggesting that although the majority of apo-
ptosis in DCA-treated cells is a direct result of efflux of
proapoptotic mediators from cancer cells, the secondary
effects on Kv channels also play an important role.
Theprecise roleofK+ channels incancer remainsunclear,
and although K+ channel opening promotes apoptosis in
several tumors, the opposite result has also been noted
(reviewed in Wang, 2004). Perhaps this relates to the type
of tumor or the well-known diversity of K+ channel families.
SpecificK+channels are nowemergingas important regula-
tors of apoptosis in different cell types. For example, HERG,
a Kv channel, mediates H2O2-dependent apoptosis in vari-
ous cancer cell lines (i.e., low HERG expression reduces
apoptosis and enhances proliferation) (Wang et al., 2002).
Kv1.5 regulates apoptosis in PASMC (Remillard and Yuan,
2004) and is downregulated in the proliferative and apopto-
sis-resistant vascular media in pulmonary hypertension
(McMurtry et al., 2004, 2005; Pozeg et al., 2003). A teleolog-
icaladvantageofKv1.5asa regulatorofapoptosis incancer,
and a factor which focused our attention on this channel,
is its very short turnover time, less than 8 hr from transcrip-
tion to functional expression (Levitan et al., 1995).
We show that cancer cells are deficient in ETC complex
I-based production of H2O2, a Kv1.5 channel opener (Fig-
ure 3B). Perhaps more importantly, Kv1.5 is downregu-
lated in cancer cell lines (Figure 4D), and Kv1.5 expression
correlates inversely with histologic grade in a cohort of
patients with non-small-cell lung cancer (more aggressive
tumors have less Kv1.5) (Figure S2). We have identified
NFAT1 as an important transcription factor responsible
for this Kv1.5 downregulation (more aggressive cancers
have more activated NFAT1) (Figure 5C).
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activation. A549 cells have increased [Ca2+]i (Figure 5A),
a direct activator of calcineurin and thus NFAT (Macian,
2005). This increase in [Ca2+]i is, at least in part, due to
the increased Ca2+ influx that results from the Kv channel
deficiency (Figure 4). In addition, calcineurin is inhibited by
increased ROS levels (Namgaladze et al., 2005); thus, the
low mitochondrial ROS in cancer (Figures 3B and 7B)
promote NFAT activation. Furthermore, the acidotic envi-
ronment in cancer (due to aerobic glycolysis) (Figure 2E)
would further promote NFAT activation (Komarova et al.,
2005). It is remarkable that all of thesemechanisms are re-
versed by DCA, which increases ROS, increases pH, and
decreases [Ca2+]i, explaining its impressive effects on
NFAT (Figure 5B). The upregulation of Kv1.5 by a drug
that directly affects mitochondrial function suggests the
presence of the mitochondria-NFAT-Kv1.5 axis, which is
suppressed in cancer. Our work suggests that potential
effects on Kv channels should be considered in cancer
therapies targeting the mitochondria.
Metabolic Modulation in Cancer by DCA: Possibility
of Prompt Translation to Clinical Oncology
Our work suggests that metabolic modulators could be
beneficial in human cancer, either alone or in combination
with traditional chemotherapies, as apoptosis sensitizers.
By targeting a fundamental and unique property of cancer
cells, this approach may combine efficacy and selectivity.
DCA (in clinically relevant doses; Stacpoole et al., 2006)
was effective in preventing and inhibiting tumor growth
in established tumors both early (week 2) and late (week
10) in their development (Figure 8A). DCA’s effects in the
reversal protocols were immediate, with significant effects
even after 1 week of treatment. The relative specificity of
DCA to target a metabolic (mitochondria) and electric
(K+ channels) remodeling was confirmed by microarray
experiments, where pathway analysis revealed a short
list of altered mitochondrial apoptosis cell cycle and ion
channel genes (Supplemental Results; Figure S6).
A very attractive property of DCA is its selectivity,
evident by the lack of any systemic toxicity in this (Fig-
ure 8D) and other recent animal (McMurtry et al., 2004)
and human studies (Stacpoole et al., 2006). DCA’s ability
to ‘‘restore’’ DJm might explain why it is effective prefer-
entially in cells that have very high DJm, such as cancer
cells, but has no effects in normal cells (epithelial, fibro-
blasts, or PASMC). Preferential expression of PDK might
also contribute to its selectivity. In a recent study of non-
small-cell lung cancer specimens, cancer cells had in-
creased PDK2 and decreased PDH expression (compati-
ble with a glycolytic phenotype) compared to neighboring
nonmalignant cells (Koukourakis et al., 2005).
The small size of DCA results in excellent tissue penetra-
tion after oral intake, including the central nervous system
(Stacpoole et al., 2003), relevant to the difficult-to-treat
glioblastoma, one of the tumors that we studied in vitro.
In addition, DCA decreases tumor lactic-acid production
and increases intracellular pH (Figure 2E); future studies
need to address the hypothesis that this will decreasetumor invasiveness and metastatic potential (Gatenby
and Gillies, 2004).
Our work identifies the mitochondria-NFAT-Kv channel
axis and PDK as critical components of the metabolic-
electrical remodeling that characterizes many human
cancers and offers a tantalizing suggestion that DCA
may have selective anticancer efficacy in patients. The
very recent report of the first randomized long-term
clinical trial of oral DCA in children with congenital lactic
acidosis (at doses similar to those used in our in vivo
experiments) showing that DCA was well tolerated and
safe (Stacpoole et al., 2006) suggests a potentially easy
translation of our work to clinical oncology.
EXPERIMENTAL PROCEDURES
The use of human tissues was approved by the University of Alberta
Human Ethics Committee, and all experiments with rodents were
approved by the University of Alberta Animal Ethics Committee (Health
Sciences Laboratory Animal Services).
Confocal Microscopy
Imaging was performed using a Zeiss LSM 510 multiphoton confocal
microscope (Carl Zeiss Canada, Toronto, ON) and multiple-staining
techniques, as previously described (McMurtry et al., 2004, 2005).
For details, see Supplemental Data.
Metabolic Studies
A549 cells were grown to confluency in T-175 flasks and rates of
glycolysis, fatty acid oxidation, and glucose oxidation were measured
as previously described (Saddik et al., 1993) in the presence or
absence of DCA (0.5 mM, 48 hr); also see Supplemental Data.
Ca2+ Measurements
Intracellular free Ca2+ concentration ([Ca2+]i) was studied in live A549
cancer cells using FLUO-3AM (Invitrogen-Molecular Probes Canada,
Burlington, ON). Cells were loaded with FLUO-3AM (5 mmol/l) for 45
min (37C) in serum-free medium and washed for 30 min in PBS
(37C) to allow cleavage of the acetoxymethyl esters. In association
with FLUO-3, Hoechst (1.0 mmol/l) nuclear staining was applied for
10 min (Molecular Probes). Fluorescence was measured at 505–535
nm with excitation at 488 nm.
H2O2 Measurements
Cancer cells were propagated on LabTek multiwell slides (Nalge Nunc,
Rochester, NY, USA; VWR, Mississauga, ON, Canada) until confluent.
Monolayers were preincubated with DCA in the presence or absence
of 5 mM rotenone (Sigma-Aldrich Canada, Oakville, ON) for 1 hr. Pro-
duction of H2O2 was measured by the AmplexRed assay (Molecular
Probes). Fluorescence was measured at 590 nm with excitation at
530 nm, and H2O2 levels were determined by reference to a standard
curve, as previously described (McMurtry et al., 2004).
Electrophysiology
With standard whole-cell patch-clamping techniques, cells were volt-
age clamped at a holding potential of 70 mV and currents were
evoked by 200 ms test pulses from 70 to +70 mV with 20 mV steps,
filtered at 1 kHz, and sampled at 2–4 kHz, as previously described
(McMurtry et al., 2004, 2005).
Immunoblotting and Quantitative Real-Time Polymerase
Chain Reaction
For details, antibodies, and primers, see Supplemental Data.
Kv1.5 Gene Transfer
A549 cells were infected with replication-deficient serotype-5 adeno-
virus encoding genes for GFP and cloned human Kv1.5 (both underCancer Cell 11, 37–51, January 2007 ª2007 Elsevier Inc. 49
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et al., 2005; Pozeg et al., 2003). We achieved 80% infection rates, and
infected cells were selected on the basis of their green fluorescence.
In Vivo Tumorigenicity Assays
A cell suspension of A549 cells in PBS (33 106 cells per injection) was
injected subcutaneously into nude athymic rats. Rats were divided into
control (no treatment), prevention, and reversal groups, and two proto-
cols were followed. In protocol a, rats were followed for 5 weeks: the
prevention group was treated for 5 weeks and the reversal group for
3 (weeks 3–5). In protocol b, rats were followed for 12 weeks, with
the prevention group treated for 12 weeks and the reversal group
fromweek 10 toweek 12. In both protocols, DCA (0.075 g/l) was added
to the drinking water. By measuring the amount of water consumed,
we calculated and adjusted the concentration of DCA required to
achieve a daily dose similar to that used clinically (50–100 mg/kg)
(McMurtry et al., 2004; Stacpoole et al., 2006) Rats were observed
weekly for the appearance of tumors at injection sites, and tumor
size was measured every week with calipers in the three groups.
Intracellular K+
IntracellularK+wasstudied ratiometrically,measuring the fluorescence
of cells loaded with the acetoxymethyl ester form of PBFI (PBFI-AM;
5 mM; Molecular Probes). For details, see Supplemental Data.
Mitochondrial NADH
Mitochondria were isolated from both untreated and DCA-treated cells
(500 mM, 48 hr), as previously described (Michelakis et al., 2002). Mito-
chondrial NADH ([NADH]m) was assessed using the methods de-
scribed previously by Brandes and Bers (1996). The mitochondria
were excited by light at 350 nm, and fluorescence was detected at
456 nm using a Photon Technology International Delta Scan 1 fluores-
cence spectrophotometer (London, ON, Canada). The fluorescence
signal at 456 nm is known to predominantly arise from [NADH]m
(Eng et al., 1989).
PDH Activity
PDH activity was assessed by measuring the amount of phosphory-
lated and unphosphorylated E1a subunits. Three milligrams of protein
was isolated from untreated and DCA-treated cells. PDH subunits
were isolated using the PDH complex immunocapture kit (MitoScien-
ces, Eugene, OR, USA). The immunoprecipitated fraction was then
used for immunoblotting using the human PDH subunits monoclonal
antibody cocktail (MitoSciences).
siRNA Studies
A549 lung cancer cells were grown to 80% confluence in six-well
culture dishes. The transfection agent siPORTamine (Ambion siRNA
Transfection II kit 1631, Ambion, Austin, TX) was preincubated at
room temperature for 10 min at a ratio of 1:12 in OptiMEM1 culture
medium (Invitrogen-GIBCO Canada, 31985-070, Burlington, ON).
This concentration of transfection agent had previously been demon-
strated to result in at least 60% gene knockdown with less than 15%
cell death (data not shown). The mixture was combined with 75,
37.5, or 18.7 nmol of scrambled versus silencer RNA for human
PDK2 and PDK1 (Ambion) in an equivalent volume of OptiMEM1,
and incubated for a further 10 min. The PDK2 silencer variants ID
264, 265, and 266 were also tested. The culture mediumwas aspirated
from the cells, the transfection agent-RNA complex mixture was
allowed to spread over the monolayer, and 1.5 ml of complete F12K
was added. Plates were incubated at 37C for 48 hr.
Cell Cultures
For sources of cell lines and culture media, see Supplemental Data.
Magnetic Resonance Imaging, DNA Microarrays, Intracellular
pH Measurement, and Lactate Measurement
See Supplemental Data.50 Cancer Cell 11, 37–51, January 2007 ª2007 Elsevier Inc.Statistics
Values are expressed as the mean ± SEM. Intergroup differences were
assessed by Kruskal-Wallis or one-way ANOVA as appropriate, with
post hoc analysis using Fisher’s exact test (Statview 4.02, SAS Insti-
tute, Cary, NC, USA).
Supplemental Data
Supplemental Data include six figures and Supplemental Results
and Supplemental Experimental Procedures, and can be found with
this article online at http://www.cancercell.org/cgi/content/full/11/1/
37/DC1/.
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